Loading market movers...

Docetaxel 75 mg/m2

Phase 3

00%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q2 '27

BAYRYPhase 3$42.5B

Docetaxel 75 mg/m2 Phase 3 Est. Readout

Docetaxel 75 mg/m2• Prostate Cancer732

Q2 2027~QConfirmed

00%

Competitive Landscape

7 competitors in Prostate Cancer

CADLaglatimagene besadenovec

CASIPanzem® NCD

SNYCabazitaxel XRP6258

View Full Landscape

Drug Information

Target Indication

Prostate Cancer

Clinical Trial

Last updated: 9/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BAYRY

BAYER

Healthcare•Europe•NASDAQ

Related Pipeline

D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3

Acute Coronary Syndrome

Oxybutynin (Oxytrol, BAY839380)Phase 3

Overactive Bladder

Amikacin Inhalation Solution (BAY41-6551)Phase 3

Pneumonia, Bacterial

Finerenone (Kerendia, BAY94-8862)Phase 3

Chronic Kidney Disease

Regorafenib (Stivarga, BAY73- 4506)Phase 3

Colorectal Neoplasms

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts